Data Insights

BGB-30813 by BeiGene for Cervical Cancer: Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Cervical Cancer

Data Insights

BGB-30813 by BeiGene for Gastric Cancer: Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Gastric Cancer

Data Insights

BGB-30813 by BeiGene for Small-Cell Lung Cancer: Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Small-Cell Lung Cancer

Data Insights

BGB-30813 by BeiGene for Solid Tumor: Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Solid Tumor

Data Insights

BGB-30813 by BeiGene for Endometrial Cancer: Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Endometrial Cancer

Data Insights

BGB-30813 by BeiGene for Non-Small Cell Lung Cancer: Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Non-Small Cell Lung Cancer

Data Insights

BGB-30813 by BeiGene for Esophageal Cancer: Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Esophageal Cancer

Data Insights

BGB-30813 by BeiGene for Nasopharyngeal Cancer: Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Nasopharyngeal Cancer

Data Insights

BGB-30813 by BeiGene for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Gastroesophageal (GE) Junction Carcinomas

Data Insights

BGB-30813 by BeiGene for Merkel Cell Carcinoma: Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Merkel Cell Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Merkel Cell Carcinoma

Data Insights

BGB-30813 by BeiGene for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Triple-Negative Breast Cancer (TNBC)

Data Insights

BGB-30813 by BeiGene for Malignant Mesothelioma: Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Malignant Mesothelioma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Malignant Mesothelioma

Data Insights

BGB-30813 by BeiGene for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Cutaneous Squamous Cell Carcinoma (cSCC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Cutaneous Squamous Cell Carcinoma (cSCC)

Data Insights

BGB-30813 by BeiGene for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

BGB-30813 by BeiGene for Metastatic Melanoma: Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Metastatic Melanoma

Data Insights

BGB-30813 by BeiGene for Metastatic Renal Cell Carcinoma: Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Metastatic Renal Cell Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Metastatic Renal Cell Carcinoma

Data Insights

BGB-30813 by BeiGene for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Metastatic Transitional (Urothelial) Tract Cancer

Data Insights

BGB-30813 by BeiGene for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....

Likelihood of Approval and Phase Transition Success Rate Model - BGB-30813 in Head And Neck Squamous Cell Carcinoma (HNSC)